Table 4.
Patient characteristics of four groups
| Group 1 | Group 2 | Group 3 | Group 4 | |
|---|---|---|---|---|
| PD‐L1 TPS | <50% | <50% | ≥50% | ≥50% |
| sPD‐L1 (pg/mL) | <90 | ≥90 | <90 | ≥90 |
| Characteristics | (N = 68) | (N = 9) | (N = 60) | (N = 18) |
| Age | ||||
| Median (range) | 64 (30–84) | 64 (36–79) | 63.5 (34–85) | 63 (48–770 |
| ≧75 years | 6 (9%) | 1 (11%) | 12 (20%) | 3 (17%) |
| Gender | ||||
| Female | 25 (37%) | 4 (44%) | 19 (32%) | 5 (28%) |
| Male | 43 (63%) | 5 (56%) | 41 (68%) | 13 (72%) |
| ECOG PS | ||||
| 0–1 | 63 (93%) | 7 (78%) | 54 (90%) | 15 (83%) |
| 2 | 5 (7%) | 2 (22%) | 6 (10%) | 3 (17%) |
| Smoking status | ||||
| Never | 15 (22%) | 3 (33%) | 12 (20%) | 2 (11%) |
| Current to former smoker | 53 (78%) | 6 (67%) | 48 (80%) | 16 (89%) |
| Histology | ||||
| Squamous | 17 (25%) | 3 (33%) | 10 (17%) | 2 (11%) |
| Nonsquamous | 51 (75%) | 6 (67%) | 50 (83%) | 16 (89%) |
| EGFR | ||||
| Wild‐type | 44 (65%) | 4 (44%) | 41 (68%) | 12 (67%) |
| Mutation | 8 (12%) | 1 (11%) | 11 (18%) | 3 (17%) |
| PD‐L1 TPS | ||||
| < 50% | 68 (100%) | 9 (100%) | 0 | 0 |
| ≧ 50% | 0 | 0 | 60 (100%) | 18 (100%) |
| Treatment‐line | ||||
| 1 | 5 (7%) | 1 (11%) | 26 (43%) | 5 (28%) |
| 2–3 | 63 (93%) | 8 (89%) | 34 (57%) | 13 (72%) |
| CRP | ||||
| Median (range) | 0.655 (0.01–19.44) | 6.45 (0.31–14.49) | 0.785 (0.04–12.41) | 8.51 (1.19–23.89) |
| < 1.31 | 42 (62%) | 1 (11%) | 36 (60%) | 2 (11%) |
| ≧ 1.31 | 26 (38%) | 8 (89%) | 24 (40%) | 16 (89%) |
| IFN‐gamma | ||||
| Undetectable (<1.56) | 62 (91%) | 7 (78%) | 52 (87%) | 12 (67%) |
| Detectable, median (range) | 6.86 (2.84–886) | 3.49 (2.97–4.01) | 14.95 (2.88–150) | 3.48 (2.67–89) |
| Serum sPD‐L1 | ||||
| Median (range) | 63.9 (28.3–87.1) | 106(92.6–112) | 69.25 (25–89.5) | 107.5 (90.1–223) |
| No. of progression or relapse | 50 (74%) | 6 (67%) | 30 (50%) | 12 (67%) |
| No. of deaths | 31 (46%) | 4 (44%) | 17 (28%) | 10 (56%) |
CRP, C‐reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; IFN, interferon; No., number; sPD‐L1, soluble programmed death ligand 1; TPS, tumor proportion score.